Increased Fetal Hemoglobin in Patients Receiving Sodium 4-Phenylbutyrate

George J. Dover, Saul Brusilow, Dvorit Samid

Research output: Contribution to journalLetterpeer-review

127 Scopus citations


To the Editor: Increases in the production of fetal hemoglobin can ameliorate the severity of both sickle cell disease and β-thalassemia. Three groups of agents are known to increase the production of fetal hemoglobin in humans: cytotoxic drugs,1 , 2 growth factors,3 and agents that induce differentiation, such as butyrate.4 The clinical application of these drugs has been hindered by dose-limiting myelotoxicity or the requirement for continuous intravenous infusion. These difficulties may now be overcome through the exploitation of the recent discovery of sodium phenylacetate as a nontoxic inducer of differentiation affecting fetal hemoglobin production.5 Sodium phenylacetate and its pro-drug, sodium 4-phenylbutyrate,…

Original languageEnglish (US)
Pages (from-to)569-570
Number of pages2
JournalNew England Journal of Medicine
Issue number8
StatePublished - Aug 20 1992

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Increased Fetal Hemoglobin in Patients Receiving Sodium 4-Phenylbutyrate'. Together they form a unique fingerprint.

Cite this